Entry and Fusion Inhibitors
Last Updated: April 16, 2019; Last Reviewed: April 16, 2019
Maraviroc (MVC, Selzentry)
|Maraviroc (MVC, Selzentry)
For additional information see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/daf/
|Tablets: 25 mg, 75 mg, 150 mg, and 300 mg
Oral Solution: 20 mg/mL
||Selected Adverse Events
|Neonate and Infant Dose:
- Maraviroc is not approved by the Food and Drug Administration (FDA) for use in neonates or infants.
- Maraviroc is approved by the FDA for use in treatment-experienced children aged ≥2 years and weighing ≥10 kg
Recommended Maraviroc Dose for Treatment-Experienced Children Aged ≥2 Years and Weighing ≥10 kg: Tablets or Oral Solution
Recommended Maraviroc Dose for Adults: Tablets
- Nausea, vomiting
- Abdominal pain, diarrhea
- Upper respiratory tract infections
- Hepatotoxicity (which may be preceded by severe rash and/or other signs of systemic allergic reaction)
- Postural hypotension (generally seen in patients with severe renal insufficiency)
- Maraviroc is recommended for use in patients who only have CCR5-tropic HIV-1. Conduct testing with a HIV tropism assay (see Drug-Resistance Testing in the Adult and Adolescent Antiretroviral Guidelines) before using maraviroc to exclude the presence of CXCR4-tropic or mixed/dual-tropic HIV. Do not use maraviroc if CXCR4-tropic or mixed/dual-tropic HIV is present.
- Maraviroc can be given without regard to food.
- Instruct patients on how to recognize symptoms of allergic reactions or hepatitis.
- Use caution when administering maraviroc to patients with underlying cardiac disease.
Maraviroc Dosing in Patients with Hepatic Impairment:
- Maraviroc is a substrate of CYP3A4. If a patient is receiving antiretroviral agents or other medications that act as CYP3A inducers or inhibitors, the dose of maraviroc should be adjusted accordingly.
Maraviroc Dosing in Patients with Renal Impairment:
- Use caution when administering maraviroc to patients with hepatic impairment; maraviroc concentrations may be increased in these patients.
- There are no data to recommend specific doses of maraviroc in pediatric patients with mild or moderate renal impairment. Maraviroc is contraindicated for pediatric patients with severe renal impairment or end-stage renal disease on regular hemodialysis who are receiving potent CYP3A inhibitors.
- Refer to the manufacturer’s prescribing information for the appropriate doses to use in adult patients with renal impairment.